We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-24.79%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.67B
AUM Growth
-$290M
(-15%)
Cap. Flow
+$300M
Cap. Flow
% of AUM
17.92%
Top 10 Holdings %
Top 10 Hldgs %
63.16%
Holding
37
New
8
Increased
12
Reduced
6
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$182M |
| 2 |
GSK
GSK
|
+$128M |
| 3 |
Ventas
VTR
|
+$124M |
| 4 |
AbbVie
ABBV
|
+$102M |
| 5 |
Universal Health Services
UHS
|
+$79.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$191M |
| 2 |
Gilead Sciences
GILD
|
+$97.5M |
| 3 |
DaVita
DVA
|
+$75M |
| 4 |
THOR
Synthorx, Inc. Common Stock
THOR
|
+$69.9M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.42% |
| 2 | Technology | 7.76% |
| 3 | Real Estate | 5.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBIO
26
Crescent Biopharma
CBIO
$626M
| $7.98M | 0.48% |
35,000
| – | – |
|
27
Pacific Biosciences
PACB
$370M
| $7.65M | 0.46% |
+2,500,000
| New | +$10.2M |
|
28
Sutro Biopharma
STRO
$421M
| $6.12M | 0.37% |
60,000
| – | – |
|
|
NUVA
29
DELISTED
NuVasive, Inc.
NUVA
| $1.7M | 0.1% |
+33,630
| New | +$2.25M |
|
|
30
DaVita
DVA
$11.7B
| – | – |
-1,000,000
| Closed | -$75M |
|
|
31
Gilead Sciences
GILD
$165B
| – | – |
-1,500,000
| Closed | -$97.5M |
|
32
Pediatrix Medical
MD
$2.2B
| – | – |
-790,000
| Closed | -$22M |
|
33
Teva Pharmaceuticals
TEVA
$41.2B
| – | – |
-2,000,000
| Closed | -$19.6M |
|
34
CALL
Viatris
VTRS
$18.9B
| – | – |
-1,600,000
| Closed | -$32.2M |
|
|
GBT
35
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-730,000
| Closed | -$58M |
|
|
AGN
36
DELISTED
Allergan plc
AGN
| – | – |
-1,000,000
| Closed | -$191M |
|
|
THOR
37
DELISTED
Synthorx, Inc. Common Stock
THOR
| – | – |
-1,000,000
| Closed | -$69.9M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Camber Capital Management held 37 positions worth $1.67B, down 15% from $1.97B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Camber Capital Management deployed $300M of net new capital in Q1 2020, opening 8 new positions and adding to 12 existing holdings. Its largest new stake was Change Healthcare Inc. Common Stock: 13,000,000 shares worth $130M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 93% a quarter earlier, followed by Technology and Real Estate.
On the sell side, the largest reduction was Biogen, an estimated $45.5M trimmed.
- Camber Capital Management's largest Q1 2020 buy was Change Healthcare Inc. Common Stock: 13,000,000 shares worth $130M.
- Camber Capital Management added most to Ventas in Q1 2020, an estimated $124M increase.
- Camber Capital Management's biggest Q1 2020 reduction was Biogen, cutting an estimated $45.5M.
- Camber Capital Management fully exited Allergan plc in Q1 2020, selling an estimated $191M.
- Camber Capital Management's ten largest holdings make up 63% of its $1.67B portfolio in Q1 2020.
- Camber Capital Management opened 8 new positions and closed 8 in Q1 2020.
- Camber Capital Management's portfolio value fell 15% quarter-over-quarter to $1.67B.
Based on Camber Capital Management's 13F filing for Q1 2020, filed 15 May 2020.